AbbVie stock surged early Friday after beating fourth-quarter expectations, largely on the back of its immunology drugs.
The Federal Reserve's key inflation rate is still elevated but kept up its two-month streak of good readings. S&P 500 futures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback